We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Artemis Announces Collaboration Agreement with Bristol-Myers
News

Artemis Announces Collaboration Agreement with Bristol-Myers

Artemis Announces Collaboration Agreement with Bristol-Myers
News

Artemis Announces Collaboration Agreement with Bristol-Myers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Artemis Announces Collaboration Agreement with Bristol-Myers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Artemis Pharmaceuticals GmbH has announced that it has signed a target validation collaboration agreement with Bristol-Myers Squibb Company.

Under the agreement Artemis will generate various genetically-engineered murine models carrying selected genetic mutations.

Bristol-Myers Squibb will use these models in its drug discovery research activities for the validation of drug screening targets.

Such targets are used to identify compounds and therapies for the treatment of diseases for various indications in humans.

The generation of the in vivo rodent models will be based on Artemis' proprietary ArteMice™ and ArteMice™ Conditional™ technologies.

These technologies are designed to enable the introduction of genetic sequences containing the CreER gene switch for conditional gene knock out and the creation of humanized conditional mutants in which murine genes are replaced by their human orthologues.

Quality control and transfer will be done together with Artemis' strategic partner company Taconic, which also provides use licenses to Bristol-Myers Squibb covering the U.S. territory for mouse models generated by Artemis, using techniques included in the PNS and Isogenic DNA patents.

Advertisement